Cognitive Dysfunction in Systemic Lupus Erythematosus: A Case for Initiating Trials.

Area of Science:

• Neuroimmunology
• Systemic Lupus Erythematosus (SLE)
• Cognitive Dysfunction (CD)

Background:

• Cognitive dysfunction (CD) is an underdiagnosed complication of systemic lupus erythematosus (SLE), significantly affecting patient quality of life.
• Prevalence estimates for SLE-related CD vary widely (5-80%) due to inconsistent assessment methods and attribution challenges.
• Despite methodological limitations in clinical studies, evidence links SLE-related CD to established disease mechanisms.

Purpose of the Study:

• To review the current understanding of cognitive dysfunction in SLE.
• To explore proposed mechanisms underlying SLE-related CD, including neuroinflammation and blood-brain barrier disruption.
• To discuss potential therapeutic strategies and the role of neuroimaging in future clinical trials.

Main Methods:

• Review of existing clinical studies and preclinical data on SLE-related cognitive dysfunction.
• Analysis of proposed pathogenic mechanisms involving cytokines, antibodies, and neurotoxicity.
• Examination of potential therapeutic targets and neuroimaging findings.

Main Results:

• Strong evidence from mouse models and clinical data connects CD to known SLE disease mechanisms.
• Cytokines, inflammatory molecules, and autoantibodies are implicated in neuronal injury.
• Neuroimaging reveals abnormalities in brain metabolism and white matter integrity correlating with CD.

Conclusions:

• No definitive treatments for SLE-related CD currently exist.
• Potential therapeutic avenues include inhibiting microglial activation and protecting blood-brain barrier integrity.
• Neuroimaging may serve as future diagnostic tools and outcome measures for clinical trials in SLE-related CD.